Technical Analysis for CNSP - CNS Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.11 | 0.90% | 0.00 |
CNSP closed up 0.9 percent on Friday, November 1, 2024, on 85 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.90% | |
Calm After Storm | Range Contraction | 0.90% | |
NR7 | Range Contraction | 0.90% | |
Narrow Range Bar | Range Contraction | 0.90% | |
Wide Bands | Range Expansion | 0.90% | |
Down 3 Days in a Row | Weakness | 0.90% |
Alert | Time |
---|---|
Down 2 % | about 21 hours ago |
Down 1% | about 21 hours ago |
Rose Above Previous Day's High | about 24 hours ago |
20 DMA Resistance | about 24 hours ago |
Up 5% | about 24 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/13/2024
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Oncology Blastoma Glioblastoma Stage Pharmaceutical Brain Tumor Evofosfamide Central Nervous System Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Oncology Blastoma Glioblastoma Stage Pharmaceutical Brain Tumor Evofosfamide Central Nervous System Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 137.5 |
52 Week Low | 0.0955 |
Average Volume | 15,637,177 |
200-Day Moving Average | 7.30 |
50-Day Moving Average | 0.14 |
20-Day Moving Average | 0.13 |
10-Day Moving Average | 0.14 |
Average True Range | 0.03 |
RSI (14) | 37.11 |
ADX | 33.21 |
+DI | 45.51 |
-DI | 16.02 |
Chandelier Exit (Long, 3 ATRs) | 0.28 |
Chandelier Exit (Short, 3 ATRs) | 0.20 |
Upper Bollinger Bands | 0.15 |
Lower Bollinger Band | 0.10 |
Percent B (%b) | 0.19 |
BandWidth | 39.19 |
MACD Line | -0.01 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.003 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.15 | ||||
Resistance 3 (R3) | 0.15 | 0.14 | 0.14 | ||
Resistance 2 (R2) | 0.14 | 0.13 | 0.14 | 0.14 | |
Resistance 1 (R1) | 0.13 | 0.13 | 0.12 | 0.12 | 0.14 |
Pivot Point | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
Support 1 (S1) | 0.10 | 0.11 | 0.10 | 0.10 | 0.09 |
Support 2 (S2) | 0.09 | 0.10 | 0.09 | 0.08 | |
Support 3 (S3) | 0.08 | 0.09 | 0.08 | ||
Support 4 (S4) | 0.08 |